This inventor holds 5 USPTO granted patents. Top assignees: University of Florida Research Foundation Inc., H. Lee Moffitt Cancer Center and Research Institute, Inc.. Active years: 2000-2017.
Company Filing History:
5 out of 3,046 
2 out of 311 
Years Active: 2000-2017
Title: Innovations in Cancer Treatment by Thomas Cardon Rowe
Introduction
Thomas Cardon Rowe is an accomplished inventor based in Gainesville, FL (US). He has made significant contributions to the field of cancer research, particularly in developing strategies to overcome drug resistance in multiple myeloma. With a total of 5 patents, Rowe's work is paving the way for new therapeutic approaches.
Latest Patents
Rowe's latest patents focus on drug targets that aim to overcome de novo drug-resistance in multiple myeloma. One of his notable inventions involves the topoisomerase II alpha (topo IIα), which is exported from the cell nucleus in human myeloma cells through a CRM1-dependent mechanism. This process results in resistance to topo II inhibitors. Rowe identified a unique nuclear export signal (NES) of topo IIα, making it a potential target for small molecule inhibitors. His research led to the identification of small molecules that inhibit the binding of topo IIα to the export receptor CRM1, specifically targeting topo IIα without affecting p53 trafficking. These inhibitors may provide a new approach to circumvent drug resistance in multiple myeloma, offering a promising protocol for treatment.
Career Highlights
Throughout his career, Rowe has worked with esteemed institutions such as the University of Florida Research Foundation and the H. Lee Moffitt Cancer Center and Research Institute. His innovative research has garnered attention and respect within the scientific community, contributing to advancements in cancer therapeutics.
Collaborations
Rowe has collaborated with notable professionals in his field, including Volkmar Weissig and Jeffrey Allen Hughes. These partnerships have enhanced the scope and impact of his research, leading to significant findings in cancer treatment.
Conclusion
Thomas Cardon Rowe's contributions to cancer research, particularly in addressing drug resistance in multiple myeloma, highlight his role as a leading inventor in the field. His innovative approaches and collaborations continue to inspire advancements in cancer therapeutics.